Subject to the Confirmation Condition and in accordance with the Company’s succession plan, the Board appointed William Kimble as the non-executive Chairman of the Board and Ron Gusek as the Company’s Chief Executive Officer.
Departed
John C. Lee, Jr.
President and Chief Executive Officer
OLD DOMINION ELECTRIC COOPERATIVE
Effective
2025-02-01
Successor
Christopher F. Cosby
Filed
November 18, 2024, 6:59 PM ET
On November 12, 2024, John C. Lee, Jr. gave notice of his resignation as President and Chief Executive Officer ("CEO") of Old Dominion Electric Cooperative ("ODEC"), effective February 1, 2025.
Appointed
Christopher F. Cosby
President and Chief Executive Officer
OLD DOMINION ELECTRIC COOPERATIVE
Effective
2025-02-01
Filed
November 18, 2024, 6:59 PM ET
On November 12, 2024, our board of directors appointed Christopher F. Cosby as President and CEO of ODEC, effective February 1, 2025.
On November 12, 2024, Steve Richards, the Company’s Chief Executive Officer (“CEO”), announced his retirement as Chief Executive Officer of the Company, effective December 2, 2024.
the Board has appointed Scott Buchanan, the Company’s current Chief Operating Officer (“COO”) and a member of the Board, to the role of Acting CFO and Principal Financial Officer effective as of the date of Mr. Leibowitz’s resignation, while maintaining his role as the Company's COO.
Glen Leibowitz has resigned from his role as Chief Financial Officer (“CFO”) of the Company, effective November 15, 2024, for personal reasons.
Departed
Conley Chee
President and Chief Executive Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Successor
Gerald Quirk
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.
Departed
Jason Haas
Chief Financial Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Successor
Gerald Quirk
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, in connection with the reduction in workforce, the Company notified each of Conley Chee, the Company’s President and Chief Executive Officer, Jason Haas, the Company’s Chief Financial Officer, and Dr. David Roth, the Company’s Chief Medical Officer, that the employment of such officers with the Company will terminate without cause, effective as of November 22, 2024.
Appointed
Gerald Quirk
President and Chief Executive Officer
Syros Pharmaceuticals, Inc.
Effective
2024-11-22
Filed
November 18, 2024, 6:59 PM ET
On November 15, 2024, the Board of Directors appointed Gerald Quirk, Esq., currently the Company’s Chief Legal & Compliance Officer and Chief Business Officer, to serve as the Company’s President and Chief Executive Officer effective as of November 22, 2024.
Baljinder (Bal) Bhullar, Chief Financial Officer and Director Bal Bhullar was appointed to serve as CFO and Director of the Company with effect upon the closing of the Business Combination.
Appointed
(interim)
Bonnie-Jeanne Gerety
Interim Chief Financial Officer
iLearningEngines, Inc.
Effective
2024-11-12
Filed
November 18, 2024, 6:59 PM ET
the Board appointed Bonnie-Jeanne Gerety to serve as the Company’s Interim Chief Financial Officer and principal financial officer.
On November 6, 2024, the Board of Directors (the “Board”) of FREYR Battery, Inc., a Delaware corporation (the “Company”), announced the appointment of Daniel Barcelo as its CEO, effective immediately.
Departed
Steven P. Rasche
Executive Vice President and Chief Financial Officer and Chief Accounting Officer
Steven P. Rasche, the Company’s current Executive Vice President and Chief Financial Officer and Chief Accounting Officer, has announced his retirement and will continue with the Company as Senior Adviser from January 1, 2025 until his retirement on April 1, 2025.
Role change
Adam W. Woodard
Executive Vice President and Chief Financial Officer
On November 14, 2024, the Board of Directors of Spire Inc. (the “Company”) approved the appointment of Adam W. Woodard, 53, to the position of Executive Vice President and Chief Financial Officer
Departed
Steven P. Rasche
Executive Vice President and Chief Financial Officer
Steven P. Rasche, the Company’s current Executive Vice President and Chief Financial Officer and Chief Accounting Officer, has announced his retirement and will continue with the Company as Senior Adviser from January 1, 2025 until his retirement on April 1, 2025.
Departed
Anthony S. Chan
Chief Financial Officer
SHARING SERVICES GLOBAL Corp
Effective
2024-11-14
Filed
November 18, 2024, 6:59 PM ET
On November 14, 2024, Anthony S. Chan ceased to be employed by Sharing Services Global Corporation (the “Company”) or any of its subsidiaries.
On November 14, 2024, AgEagle Aerial Systems, Inc. (the “Company”) appointed Ms. Adrienne Anderson, age 46, to the positions of Interim Chief Financial Officer and Interim Principal Accounting Officer of the Company, effective immediately
Louis S. Haddad informed Armada Hoffler Properties, Inc. (the “Company”) of his decision to resign from his position as Chief Executive Officer of the Company (“Chief Executive Officer”), effective December 31, 2024.
the Board appointed Mr. Tibbetts, the Company’s President and Chief Operating Officer, to the position of Chief Executive Officer effective January 1, 2025.
Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024
On November 14, 2024, Gregory S. Lovins, Senior Vice President and Chief Financial Officer of Avery Dennison Corporation (the "Company"), began a medical leave of absence.
Appointed
(interim)
Danny G. Allouche
Senior Vice President and Interim Chief Financial Officer
On November 14, 2024, the Company’s Board of Directors (the “Board”) elected Danny G. Allouche as the Company’s Senior Vice President and Interim Chief Financial Officer, effective November 15, 2024.
On November 12, 2024, FiscalNote Holdings, Inc. (the “ Company ”) announced a leadership succession whereby Tim Hwang, the company’s current Chairman, Chief Executive Officer, and Co-founder, will transition to Executive Chairman and Josh Resnik, the company’s current President and Chief Operating Officer, will become President and Chief Executive Officer, each effective January 1, 2025.
Departed
Michael Breininger
principal financial officer and principal accounting officer
Michael Breininger, the Company’s Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company.
Appointed
Ramesh Ramachandran
principal financial officer and principal accounting officer
the Board of Directors of Ocugen, Inc. (the “ Company ”) appointed Ramesh Ramachandran to serve as the Company’s principal financial officer and principal accounting officer
On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.
Departed
Michael J. Grau
Executive Vice President and Chief Financial Officer
On November 13, 2024, Madison Square Garden Entertainment Corp. (the “Company”) and Michael J. Grau, the Company’s Executive Vice President and Chief Financial Officer, agreed that he will be leaving the Company, and effective November 20, 2024, will cease to be Chief Financial Officer.
On November 12, 2024, due to the appointment of Mr. Boggs as Chief Financial Officer of the Company, the Company amended the employment agreement ("Employment Agreement") dated December 2, 2021, with Mr. Boggs
On November 15, 2024, in relation to the retirement of Jim Stark from the Chief Financial Officer role, Mr. Stark and the Company entered into a Confidential Severance Agreement and Release
On November 15, 2024, M. Shane Bell notified the Board of Directors of First National Corporation (the “Company”) and its wholly-owned subsidiary, First Bank (the “Bank”), of his resignation as Executive Vice President and Chief Financial Officer of the Company and the Bank, effective December 2, 2024.
On November 11, 2024, Shawn Munsell gave notice of his resignation from his position as Chief Financial Officer of Calavo Growers, Inc. (“Calavo”), effective November 29, 2024.
Patricia B. Prichep, CEL-SCI’s current senior Vice President of Operations, has assumed the duties of CEL-SCI’s Chief Financial and Operations Officer, effective November 13, 2024.
On November 11, 2024, Michael Kuta notified DMC Global Inc. (the “Company”) that he will retire as the Company’s President and Chief Executive Officer and as a member of the Board of Directors (the “Board”), in each case effective as of November 29, 2024 (the “Transition Date”).
On November 12, 2024, the Board appointed James O’Leary, the Company’s Executive Chairman, as the Company’s Interim President and Chief Executive Officer, effective as of the Transition Date.
Appointed
Frank Cesario
Chief Financial Officer, Vice President Finance, Treasurer and Secretary
SIGMATRON INTERNATIONAL INC
Effective
2024-11-11
Filed
November 14, 2024, 6:59 PM ET
Effective November 11, 2024, Frank Cesario was elected Chief Financial Officer, Vice President Finance, Treasurer and Secretary of the Company.
Departed
James J. Reiman
Chief Financial Officer
SIGMATRON INTERNATIONAL INC
Effective
2024-11-08
Successor
Frank Cesario
Filed
November 14, 2024, 6:59 PM ET
On November 8, 2024, the Board of Directors (the “Board”) of SigmaTron International, Inc. (NASDAQ: SGMA), an electronic manufacturing services company (the “Company”), received notice that James J. Reiman, Chief Financial Officer of the Company, was resigning for personal reasons, effective November 8, 2024.
As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
Role change
James B. Breitmeyer
Chief Executive Officer
Oncternal Therapeutics, Inc.
Effective
2024-12-02
Filed
November 14, 2024, 6:59 PM ET
In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.
Departed
Mahesh Karande
President and Chief Executive Officer
Omega Therapeutics, Inc.
Effective
2024-11-14
Successor
Kaan Certel
Filed
November 14, 2024, 6:59 PM ET
On November 14, 2024 (the " Transition Date "), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the " Board ") of the Company, effective immediately.
Appointed
Kaan Certel
President and Chief Executive Officer
Omega Therapeutics, Inc.
Effective
2024-11-14
Filed
November 14, 2024, 6:59 PM ET
On the Transition Date, the Board appointed Kaan Certel, Ph.D., the Company’s Chief Business Officer, to serve as the Company’s President and Chief Executive Officer and elected Dr. Certel to serve as a Class I director to fill the vacancy on the Board created by Mr. Karande’s resignation, in each case, effective immediately.
Departed
Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
Effective
2024-11-14
Successor
Craig R. Jalbert
Filed
November 14, 2024, 6:59 PM ET
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.